// App-Quantinova.ai

3064.0 : Results of a first-in-human phase I study of SRF231, a fully human, high‑affinity anti‑CD47 antibody.

Researchers

Presenter

  • Amita Patnaik

Principal Investigators

  • Anna Spreafico

  • Alison M. Paterson

  • Marisa Peluso

  • Jou-Ku Chung

  • Beth Bowers

  • Demi Niforos

  • Alison M. O'Neill

  • Muralidhar Beeram

  • Marco Iafolla

  • Julia Lester

  • Alison M. Schram

Medical Centers

  • START, San Antonio, TX

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Surface Oncology, Inc., Cambridge, MA

  • eClinical Solutions, Mansfield, MA

  • 2100 Bovaird Drive, Brampton, ON, Canada

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Cluster of Differentiation 47

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Dose Escalation

  • First-In-Human

Phase

  • NA

Study Id's

  • NCT03512340

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved